CD40 and cancer: Today, more than 20 clinical trials using CD40 agonists like APX005M, Selicrelumab and CDX‐1140 are ongoing in cancer of which at least four are also including PDAC (NCT03214250, NCT02376699, NCT03329950 and NCT03193190).